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Abstract
Background: As a result of the increased consumption of sugar-rich and fatty-products, and the increase in preference
for such products, metabolic disorders are becoming more common at a younger age. Fructose is particularly used in
prepared foods and carbonated beverages. We investigated the impact of regular consumption of fructose, in
combination or not with fatty food, on the onset of metabolic syndrome and type 2 diabetes (T2D). We evaluated the
metabolic, oxidative, and functional effects on the liver and blood vessels, both related to diabetes complications.
Methods: High-fat diet (HFD), high-fructose beverages (HF) or both (HFHF) were compared to rats fed with normal
diet (ND) for 8 months to induce T2D and its metabolic, oxidative, and functional complications. Metabolic control was
determined by measuring body weight, fasting blood glucose, C-peptide, HOMA2-IR, leptin, and cholesterol; oxidative
parameters were studied by lipid peroxidation and total antioxidant capacity in plasma and the use of ROS labelling on
tissue. Histological analysis was performed on the liver and endothelial function was performed in main mesenteric
artery using organ-baths.
Results: After 2 months, HFHF and HFD increased body weight, leptin, HOMA2-IR associated to steatosis, oxidative
stress in plasma and tissues, whereas HF had only a transient increase of leptin and c-peptide. Only HFHF induced
fasting hyperglycaemia after 6 months and persistent hyperinsulinaemia and fasting hyperglycaemia with complicated
steatosis (inflammation and fibrosis) after 8 months. HFHF and HFD induced endothelial dysfunction at 8 months
of diet.
Conclusions: Six months, high fat and high carbohydrate induced T2D with widespread tissues effects. We
demonstrated the role of oxidative stress in pathogenesis as well as in complications (hepatic and vascular),
reinforcing interest in the use of antioxidants in the prevention and treatment of metabolic diseases, including
T2D.
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Background
Food and beverages rich in energy, fat, and/or sugar are
now commonly consumed in modern societies [1]. In
addition to genetic predisposition [2], physical inactivity
[1], and perinatal environment [1, 3], such diets are rec-
ognized as major causes of the obesogenic environment
in humans [1]. The consumption of large amounts of
added sugar, a prominent source of low-nutrient calories
in processed or prepared foods and caloric beverages
(i.e. soft drinks, colas) is a relatively new phenomenon
[4]. In the mid-19th century, these sweeteners became
widely available and their consumption began to increase
dramatically [5]. Fructose is used commercially as a sweet-
ening substitute (fructose corn syrup) for glucose or
sucrose, in the preparation of desserts, condiments, and
carbonated beverages [6]. It has been recently confirmed
[7] that the consumption of high amounts of refined
carbohydrates in food and beverage increases the risk of
dyslipidaemia [8], obesity [4, 6], insulin resistance [9], and
heart disease [10]. A recent epidemiological analysis in
humans also found an association between diabetes preva-
lence and sugar availability [11]. Moreover, chronic con-
sumption of a Western diet, characterized by foods rich in
sugar and abundant in total and saturated fat, has been
suggested to play a role in the development of type 2
diabetes (T2D) [12].
Diabetes is known to produce substantial changes in
intracellular metabolism in most tissues, including liver
[13]. Insulin resistance and excessive accumulation of
lipids is strongly associated with non-alcoholic fatty liver
disease (NAFLD), which represents the hepatic manifest-
ation of a systemic impairment of the insulin network [14].
In addition to being a secondary consequence of
metabolic syndrome, NAFLD is also in itself a major
risk factor for diabetes [15], and also contributes to
cardiovascular morbidity and mortality, with a two-
fold increase in the risk of death [16]. One of the alter-
ations that characterize NAFLD is hepatic steatosis, asso-
ciated with obesity, insulin resistance, diabetes mellitus,
and metabolic syndrome. Hepatic steatosis is character-
ized by the presence of hepatic fat accumulation, which,
unlike non-alcoholic steatohepatitis (NASH), is not ac-
companied by ballooning of hepatocytes [17]. NAFLD
includes a spectrum of diseases, ranging from simple fatty
liver to NASH, which may progress to end-stage liver
disease (cirrhosis) and hepatocellular carcinoma, requiring
hepatic transplantation. This pathogenesis is multifactorial
and includes lipid metabolism alterations, with an aber-
rant accumulation of triglycerides, mitochondrial dysfunc-
tion, inflammation, and oxidative stress (OS) [18].
OS, defined as an impaired balance between free
radical production and antioxidant capacity resulting
in accumulation of oxidative products [19], is a well-
recognized mechanism that plays important roles in
many pathological conditions. Several human diseases
have been closely associated with OS [20], including
aging [21], metabolic syndrome [20], and diabetes [20].
Several studies, which have proposed mechanisms to ex-
plain the increased OS in both forms of diabetes, suggest
that diabetes is a bipolar process in which, on one hand,
there is an increase in generation of reactive oxygen spe-
cies (ROS), and, on the other hand, a decrease in the levels
of plasma antioxidants levels such as vitamin E, vitamin
C, lipoic acid, and glutathione [22]. Recent studies have
shown that OS induces changes in redox balance resulting
in dysregulation of redox biology [19, 20], and plays an
important role in liver disease [18]. Moreover, OS has
been closely related to cardiovascular diseases [20] linked
with diabetes.
Diabetes-related vascular complications are an important
pathological issue which lead to the functional deterior-
ation of several organs, and cause micro- and macro-
angiopathy [23]. Large clinical studies of both forms of
diabetes have demonstrated that hyperglycaemia plays
an important role in the pathogenesis of microvascu-
lar complications [23]. Moreover, there is considerable
evidence demonstrating impairment of endothelium-
dependent vasodilatation in cardiovascular diseases. This
impairment of microvascular blood flow occurs early in
the pathogenesis of T2D, with evidence at the time of
diagnosis [24]. Dysfunction of the endothelium is regarded
as an important factor in diabetes [24] and has gained
increasing attention in the study of vascular disease.
Animal models have contributed greatly to the study
of diabetes. Such models allow researchers to control, in
vivo, genetic, and environmental factors that may
influence the development of the disease and its second-
ary complications, therefore gaining useful information
on its management and treatment in humans. There are
many animal models of obesity and T2D [25], some of
which show a genetic predisposition to the disease [26],
while others may develop the disease spontaneously [27]
or in a diet-induced manner [28]. The most commonly
used non-genetic rodent models of diabetes are those
induced by streptozotocine or alloxan, in addition to diet
[29], or models obtained by partial pancreatectomy [25]
which leads to insulin deficiency, hyperglycaemia, and
ketosis. Although these models are useful for the study
of diabetes, they are not representative of diet-induced
human metabolic syndrome and T2D. Diet composition
has been considered an important factor in the impair-
ment of insulin activity [28]. Our previous study showed
that the administration of a high-fat diet (HFD) to rats
for 2 months is a fast and easy way to induce metabolic
syndrome, associated with metabolic and oxidative dis-
orders, without modulation of glycaemia [30]. However,
recent epidemiological studies of sugar consumption
and diabetes prevalence [11] suggest that a diet rich in
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fat as well as sugar is a greater risk factor for these disor-
ders than a diet that is rich in either fats or sugars.
The aim of our study was to determine the impact of
sugar on the development of metabolic syndrome and
its evolution into T2D, as well as on the development
of related secondary complications. We compared the
impact of a diet rich in both sugar and fat with that
of a sugar-rich diet without the addition of fat. We
measured metabolic parameters such as insulin resistance,
glucose tolerance, fasting glycaemia, and compared hepatic





(ABTS) was purchased from VWR (Fontenay sous
Bois, France), amyloglucosidase (AMGD) from Roche
Diagnostic (Meylan, France), glucose and phosphate-
buffered saline (PBS) from Fisher Scientific (Illkirch,
France), eosin, Harris hematoxylin, paraffin, ethanol
and toluene from Labonord (Templemars, France).
The (+)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carbox-
ylic acid (Trolox) and all other products were purchased
from Sigma-Aldrich (St Quentin Fallavier, France).
Ethics statement
The study was performed in accordance with the “Guide
for the Care and Use of Laboratory Animals” published
by the US National Institutes of Health (NIH publication
No. 85–23, revised 1996), and the present protocol was
approved by the local ethics committee (Comité Ré-
gional d’Ethique en Matière d’Expérimentation Animale
CREMEAS, approval AL/02/11/05/12). All efforts were
made to minimize animal suffering and reduce the
number of animals used.
Animals and induction of diabetes
Sixty-five male Wistar rats (8 weeks old; 204 ± 1 g), sup-
plied by Depré (Saint Doulchard, France), were housed
in a temperature-controlled room, in a 12-h-light/dark
cycle environment with ad libitum access to water and
food. At the beginning of the study, 5 rats were sacri-
ficed (Ctr-rats, M0). After 2 weeks, the rats (312 ± 2 g)
were randomly divided into four groups of 15 rats each.
The first group had free access to a standard diet
“Normal Diet” (ND) from SAFE (Augy, France), with
the following macronutrient composition: 3.1 % fat,
16.1 % protein, 3.9 % fibre, and 5.1 % ash (minerals).
The second group “High Fructose” (HF) had the same
normal diet, but with an additional 25 % of fructose
(Sigma, France) in water. The third group, “High Fat
Diet” (HFD), received a purified laboratory hypercaloric
rodent diet “WESTERN RD” (SDS, Special Diets Services,
Saint Gratien, France) containing 21.4 % fat, 17.5 % pro-
tein, 50 % carbohydrate, 3.5 % fibre, and 4.1 % ash. The
fourth group, “High Fat High Fructose” (HFHF), had both
the enriched diet and fructose in water. Both groups had
free access to water. The body weight and calorie intake of
each animal was recorded once a week. 5 rats were sacri-
ficed at the beginning of the study (M0), and then 5 rats
of all groups were sacrificed at 2 and 8 months (M) after
starting administration of each diet.
Sacrifice
Before anaesthesia, body weight was recorded, capillary
glucose levels were measured, and tail vein blood samples
were taken to estimate metabolic parameters. After anaes-
thesia with an intraperitoneal injection of 50 mg/kg pento-
barbital (Centravet, France), blood was drawn from the
abdominal aorta, and plasma and serum were frozen in
liquid nitrogen and stored at −80 °C after centrifugation
(4 °C, 2 min, 10,000 × g) for later biochemical analysis.
Liver tissue was cleaned, weighed and embedded in
Tissue-Tek® OCT (Optimal Cutting Temperature com-
pound, Leica Microsystem SAS, Nanterre, France) or
directly frozen in liquid nitrogen and stored at −80 °C.
The main superior mesenteric artery was excised and
bathed in Krebs bicarbonate solution (119 mM NaCl,
4.7 mM KCl, 1.18 mM KH2PO4, 1.18 mM MgSO4, 1.25
mM CaCl2, 25 mM NaHCO3, and 11 mM D-glucose,
pH 7.4, 37 °C) for dissection.
Biochemical plasmatic analysis
Plasmatic metabolic parameters
Glucose tolerance was evaluated by measuring intraperito-
neal glucose tolerance (IpGTT) of fasting rats. Capillary
glycaemia at baseline and 15, 30, 60, and 120 min after an
intraperitoneal (IP)-injection of 2 g/kg glucose (20 %
solution) was measured with a glucometer (Accu-Chek
Performa®, Roche Diagnostic, France). Blood samples were
collected from the tail vein at 0 and 60 min after injection,
in order to measure blood glucose (glucose RTU®, Biomér-
ieux, France) and C-peptide levels (Elisa C-peptide kit,
Mercodia, Uppsala, Sweden) to evaluate insulin sensitivity.
Measuring C-peptide was preferred to measuring insulin
for evaluating insulinemia, because it is more stable in
blood and is not affected by haemolysis [31]. Results were
expressed in g/L for plasma glucose and in pmol/L for
plasma C-peptide. Fasting leptin was measured by ELISA
(Elisa Leptin kit, Linco Research Inc., St Louis, MO, USA)
as An index of fat mass [32]. Plasmatic cholesterol was
quantified by a colorimetric method Cholesterol RTU™
(BioMérieux, Lyon, France) using a cholesterol calibrator.
Insulin resistance was evaluated using the homeostasis
model assessment (HOMA2). HOMA2-IR was calculated
for fasting plasma glucose and fasting C-peptide using the
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HOMA2 model calculator (http://www.dtu.ox.ac.uk/homa-
calculator). All parameters were measured once a month.
Plasmatic inflammatory and oxidative parameters
TNFα was assessed on plasma according to the manu-
facturer’s instructions (Rat TNF-α ELISA Kit, Millipore,
Fontenay sous Bois, France). Total antioxidant capacity
(TAOC) with the radical cation ABTS•+ was performed
by a trolox equivalent antioxidant capacity method as
previously described [30]. Lipid peroxidation as a conse-
quence of OS was estimated by measuring TBARS using
a kit (OxiSelect™ TBARS Assay Kit-MDA Quantitation,
Cell Biolabs Inc., San Diego, CA, USA) according to the
manufacturer’s instructions, and expressed in μmol/L
TBARS.
Histological and functional studies
Morphological analysis and immunohistochemistry
The degree of hepatic histological changes was assessed
by eosin/hematoxylin coloration, Oil Red O (steatosis),
and Masson’s Trichrome (fibrosis) staining on 10-μm
cryosections fixed with 4 % paraformaldehyde. Steatosis
was evaluated according to the standard Kleiner Classifi-
cation [33] of grading and staging. Degree of steatosis
was scored as the percentage of hepatocytes per lipid
droplet: 0 (less than 5 %), 1 (between 5 and 33 %), 2
(between 33 and 66 %) and 3 (higher than 66 %), com-
plicated or not by fibrosis.
In situ liver macrophages
As previously described by Dal S et al. [34] frozen-
embedded liver sections (10 μm) were fixed and incu-
bated with rabbit anti-Iba-1 (Rat, 1:1000, Wako Chemicals
GmbH, Germany). Macrophage density was expressed as
the percentage of brown pixels per field in comparison to
control values (100 %). Six slides were prepared for each
animal, and five fields were analysed per slide at a magnifi-
cation of × 20.
Hepatic triglycerides and glycogen quantification
Extraction of hepatic triglyceride content was performed
on piece of fresh liver (100 mg) mixed with a high-speed
homogeniser (Polytron PT MR2100, Kinematica AG,
Luzern, Switzerland) in a chloroform and methanol
buffer (CHCl3/Methanol/H2O, v/v: 2/1/0,6), and centri-
fuged (1000 × g, 10 min, ambient temperature). The clot
was mixed with a fresh solution of chloroform-Triton
(X100, 2 %), evaporated (55 °C), and diluted in milli-Q
water. Triglycerides were determined using the Triglycer-
ides Quantification Kit (Abcam, Paris, France) according
to the manufacturer’s instructions. Samples were mea-
sured at 550 nm and concentrations were expressed in
nmol/mg of liver.
Hepatic glycogen content extraction was performed
on piece of fresh liver (100 mg) according to the
method described previously [34] and expressed in mg
of glycogen/mg of liver.
Tissue oxidative stress
The oxidative fluorescent dye dihydroethidine (DHE)
was used to evaluate in situ formation of ROS according
to a method described by Dal-Ros et al. [34]. Unfixed
liver and mesenteric artery were cut into 10-μm-thick
sections, treated with DHE (2.5 μM), and incubated in a
light-protected humidified chamber at 37 °C for 30 min.
The level of ROS was determined using microscopy and
whole fluorescence of tissue was quantified with the
microscope assistant (NIS-Elements BR, Nikon, France),
and expressed as a percentage of that in age-matched
ND rats.
As previously described [35], liver tissue (5 mg) from
experimental rats was homogenized using NP-40 buffer
(NaCl 150 mmol/L, 1.0 % Triton X-100, Tris 50 mmol/L,
pH 8) with a protease/phosphatase inhibitor cocktail
(Roche Diagnostics, Meylan, France) using an ULTRA-
TURRAX. Supernatants were collected and protein con-
tents measured by the Bradford method [36] SOD and
catalase activities were performed (50 mg of proteins)
according to the manufacturer’s instructions (Superoxide
dismutase assay kit and Catalase Assay Kit, Abcam, Paris,
France) and expressed respectively in % of inhibition
rate and (μmol/L). Lipid peroxidation was estimated
by measuring TBARS using a kit (OxiSelect™ TBARS
Assay Kit-MDA Quantitation, Cell Biolabs Inc., San
Diego, CA, USA) according to the manufacturer’s
instructions, and expressed in μmol/L TBARS/mg of
proteins.
Vascular reactivity studies
Mesenteric artery rings were suspended in organ baths
for the determination of changes in isometric tension,
as described previously [21]. The NO-mediated compo-
nent of relaxation was determined in the presence of
indomethacin (10 μM) and charybdotoxin (CTX) plus
apamin (APA) (100 nM each) to rule out the formation
of vasoactive prostanoids and EDHF, respectively. The
EDHF-mediated component of relaxation was deter-
mined in the presence of indomethacin (10−5M) and
NѠ-nitro-L-arginine (L-NA, 10−4M) to rule out the
formation of vasoactive prostanoids and NO, respect-
ively. Levcromakalim- (an ATP-sensitive K+channel
opener; 0.1 nM–10 μM) induced relaxations were ex-
amined in endothelium-denuded rings of mesenteric
artery to test the vascular smooth muscle cells relax-
ations without EDHF production by endothelial cells.
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Statistical analysis
Values are expressed as means ± SEM, and n indicates
the number of rats. Statistical analysis was performed with
Student’s t-test for unpaired data or ANOVA followed by
Tukey’s protected least-significant difference test, where
appropriate (Statistica®, StatSoft, France). p < 0.05 was
considered to be statistically significant.
Results
Metabolic follow-up
After 3 weeks of diet, HFHF and HFD induced a sig-
nificant increase in body weight (p < 0.05) maintained
until the end of the study, in comparison to HF and
ND diet (respectively, 863 ± 72 g; 863 ± 70 g; 680 ± 22 g
and 617 ± 9 g) (Fig. 1a). After 2 months, fasting glycaemia
Fig. 1 Weight and glucose tolerance measured during the study. a Weight during the study for the normal diet (ND, ○), normal diet + fructose
(HF, ●), high fat diet (HFD, □) and HFD+ fructose (HFHF, ■) groups. * Global significant results versus age-matched ND-rats. b Evolution of glycaemia
and the area under the curves (AUC) during intraperitoneal glucose tolerance (IpGTT) test on fasting rats (0) and 15, 30, 60, 120 min after
glucose injection in all groups and at the beginning (Ctr-rats, M0) and after 2 (M2) and 8 (M8) months of diet. Results are shown as
mean ± SEM of 5 different experiments. * Significant results versus age-matched ND-rats
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(Tables 1, 2 and 3) was higher in HFD and HFHF rats.
Moreover, AUC after ipGTT was higher in hypercaloric
diet (HF, HFD and HFHF) (respectively: 229 ± 20; 221 ± 12
and 271 ± 30; p < 0.01) (Fig. 1b). C-peptide levels in pre-
and post-ipGTT were also higher in the 3 groups as
compared to those in ND-rats (Tables 1, 2 and 3). After
2 months, HOMA2-IR values were higher than 2.4 in HF,
HFD, and HFHF rats, confirming insulin resistance, but
only significantly increased in HFD and HFHF rats as
compared to ND rats (p < 0.01) (Tables 1, 2 and 3). After
4 months, fasting glycaemia was the same in all groups
around 104.5 ± 3mg/dL and only HFHF rats shown fast-
ing glycaemia under 126 mg/dL (147 ± 7 mg/dL) after
6 months of diet in comparison to ND, HF and HFD
(respectively: 103 ± 2; 114 ± 3 and 105 ± 2 mg/dL) (data
not shown).
After 8 months, HFHF maintained all metabolic pa-
rameters disorders such as higher fasting leptinaemia,
fasting glycaemia, fasting and post-ipGTT C-peptide, as
indicated by the AUC (p < 0.05) and HOMA2-IR (p <
0.001). Glycaemia at 2 h post-ipGTT was increased to
greater than 200 mg/dL in HFD rats and associated with
a higher level of C-peptide, but without significant in-
crease in fasting glycaemia or HOMA2-IR, as compared
to HF or ND rats (Tables 1, 2 and 3). Total cholesterol
increased in HFHF rats from 2 months in comparison to
ND rats (p < 0.05), whereas this effect was not observed
for HFD and HF rats (Tables 1, 2 and 3).
Inflammatory and oxidative follow-up
HFHF and HFD induced respectively an increase of five
and four times of the plasmatic TNFα after 8 months
(Table 4). Moreover, lipid peroxide levels increased also
after 8 months in HFHF and HFD rats (Table 4),
whereas HF had no effect on these inflammatory and
OS parameters. During the study, the total antioxidant
capacity was comparable in all groups, in spite of OS
(Table 4).
HFHF and hepatic complications
HE analysis of the liver showed marked vacuolar degen-
eration in HFHF and HFD rats, indicating hepatic fat
accumulation (Fig. 2a). Oil-red O-staining confirmed the
accumulation of lipid droplets in HFHF and HFD rats.
Steatosis increased between 2 and 8 months in HFHF
and HFD rats (steatosis score: 1–2 to the maximum 3,
according to Kleiner et al. [32]), associated with fibrosis
and macrophage infiltration after 8 months only in HFHF
rats. In fact, the HFHF diet was found to result in an
increase in hepatic macrophages (p < 0.01) in comparison
to HFD, HF and ND (Fig. 2a and Table 4). Biochemical
analysis of the hepatic triglyceride content confirmed lipid
accumulation, with a significant increase in triglycerides
after 2 months, which was maintained after 8 months
(Fig. 2b). The level of hepatic glycogen content was com-
parable in HFHF and ND rats during the study. HF was
found to gradually increase glycogen levels from 2 to
8 months, whereas HFD transiently increased glycogen
levels at 2 months (Fig. 2c).
HFHF induced a significant and persistent increase in
hepatic ROS levels from 2 months and throughout the
study in comparison to ND, without TBARS formation.
HFD induced only a transient hepatic ROS formation
after 2 months, not associated to TBARS complication.
HF induced a transient increase of TBARS (p < 0.01)
without ROS formation (Fig. 2a and Table 4). In spite of
ROS observed in the liver, SOD and catalase activities
were comparable in all groups during the study, excepted
after 8 months in HF-rats where catalase activity was
decreased (p < 0.01) (Table 4).
HFHF and vascular function
The cumulative addition of acetylcholine caused concentration-
dependent relaxations in isolated mesenteric arteries of
Ctr-rats in the presence of indomethacin (10 μM) and
Nω-nitro-L-arginine (100 μM) (Fig. 3). This EDHF-
mediated component of relaxation is strongly decreased
after 8 months in ND and HF rats and abolished in
HFHF and HFD rats. The concentration-dependent relax-
ation induced by levcromakalim (0.1 nM–10 μM), an
ATP-sensitive K+ channel opener, in mesenteric arteries
from all groups, was maintained (respectively: relaxant
effect at 10 μM, 94.5 ± 7.0 % in mesenteric arteries from
Ctr-rats at M0 and at M8: 96.7 ± 0.9 % in ND-rats,
96 ± 2.2 % in HFHF-rats, 98 ± 0.7 % in HFD-rats and
103.5 ± 3.2 % in HF-rats, data not shown). Moreover,
in the presence of indomethacin, Nω-nitro-L-arginine,
and charybdotoxin plus apamin, acetylcholine-induced
relaxations were abolished in all groups (data not shown).
Altogether, these results indicate that the EDHF-
mediated component of relaxation is abolished by HFHF
and HFD after 8 months, regardless of the age of rats.
Table 1 Evolution of metabolic parameters during the study
M0 Ctr
Weight (g) 300 ± 6
Fasting Leptin (ng/mL) 3.5 ± 0.4
Fasting glycaemia (mg/dL) 83 ± 3
Peptide-C (pmol/L) Fasting 860.5 ± 56.8
Non-fasting 1283.6 ± 115.3
Insulin resistance (HOMA2-IR) 1.22 ± 0.08
Total cholesterol (mM) 2.20 ± 0.49
Effects of diet on body weight and metabolic parameters during the study,
at the beginning (M0) of normal diet (ND), normal diet + fructose (HF), high fat
diet (HFD) and HFD + fructose (HFHF)
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Moreover, HFHF induced a significant and persistent
increase in hepatic ROS levels from 2 months and through-
out the study, in comparison to ND. HFD induced only a
transient hepatic ROS formation after 2 months and HF
had no effect on hepatic ROS (Fig. 2a and Table 4).
Discussion
The present study demonstrates that only the combination
of sugar and fat, present in beverage and diet (HFHF),
allowed the development of T2D associated with long-term
metabolic disorders such as maintenance of fasting hyper-
glycaemia, pre- and post-prandial hyperinsulinaemia, insu-
lin resistance, glucose intolerance, and dyslipidaemia
(hypertriglyceridaemia and hypercholesterolaemia). More-
over, HFHF was found to induce T2D-associated complica-
tions such as hepatic steatosis complicated by fibrosis,
inflammation, and OS in the animals, regardless of their
age. In addition, HFHF and HFD induced obesity associated
with hyperleptinaeemia and endothelial dysfunction. How-
ever, HFD alone induced only transient insulin resistance,
glucose intolerance, and hypertriglyceridaemia, without any
impact on total cholesterol. In contrast, ND rats showed a
decrease in insulin sensitivity, associated with glucose
intolerance, with increasing age, thus minimizing the effects
provided by the HFD. A transient metabolic disorders
appears after 2 months of fructose beverage-intake only,
characterized by a reduction of insulin sensitivity without
abnormal weight gain, which may be due to an expansion
of adipose cells [37] suggesting by hyperleptinaemia, even
though total calorie intake (food and beverage, data not
shown) did not differ between groups. These results are in
accordance with the very few studies in humans reporting
that the effects of fructose-rich diets, particularly on insulin
sensitivity, appear to be dose-dependent [38, 39]. However,
the dose of fructose administrated to rodents was higher
(50–60 % of the diet) than that administered to humans
(10–15 %).
Excessive consumption of fructose may affect the liver
[40]. Indeed, this was found to increase the production
of glycogen in HF and HFHF rats after 2 and 4 months.
The conversion of glucose into glycogen is a key path-
way by which the liver removes glucose from the portal
vein after a meal, mediated by the bidirectional GLUT2
transporter and through gluconeogenesis [41]. Koo et al.
[42] showed that liver glycogen is higher in HF-rats,
indicating its conversion by gluconeogenesis. This in-
crease in glycogen may represent a protective mechanism
against fat accumulation in the liver [43], and against
hyperglycaemia [44], as observed in the HF rats. However,
after 8 months of HFHF, hepatic OS resulted in a decrease
in the levels of glycogen, as reported by Castro MC et al.
[45], throughout a NADPH oxidase pathway. Less signifi-
cantly, after 2 months of HFD, the hepatic glycogen level
was found to have increased through a second mechanism
Table 3 Evolution of metabolic parameters during the study
M8 ND HF HFD HFHF
Weight (g) 617 ± 9 680 ± 22 863 ± 70*** 863 ± 72***
Fasting Leptin (ng/mL) 22.41 ± 1.48 26.13 ± 1.45 91.17 ± 13.8** 124.11 ± 5.09**b
Fasting glycaemia (mg/dL) 124 ± 5 122 ± 4 116 ± 2 137 ± 2*b
Peptide-C (pmol/L) Fasting 1871.8 ± 259 2060.7 ± 180.0 2730 ± 365.1 3937.3 ± 4953.1*
Non-fasting 3534.8 ± 185.8 6081.3 ± 987.2 6615 ± 828.3* 12411.7 ± 2072.4**a
Insulin resistance (HOMA2-IR) 4.53 ± 0.62 4.97 ± 0.44 5.7 ± 0.82 9.78 ± 1.24***
Total cholesterol (mM) 1.76 ± 0.24 2.44 ± 0.51 3.0 ± 0.59 4.23 ± 0.47*
Effects of diet on body weight and metabolic parameters during the study, after 8 months (M8) of normal diet (ND), normal diet + fructose (HF), high fat diet
(HFD) and HFD + fructose (HFHF). In bold significant difference with * vs. age-matched ND rats and a, bbetween HFD- and HFHF-rats. *p<0.05; **p<0.01;
***p<0.001 and ap<0.05 and bp<0.001
Table 2 Evolution of metabolic parameters during the study
M2 ND HF HFD HFHF
Weight (g) 442 ± 610 462 ± 8 543 ± 14* 553 ± 14*
Fasting Leptin (ng/mL) 8.19 ± 0.44 10.84 ± 0.75** 20.86 ± 0.79*** 17.05 ± 1.68***a
Fasting glycaemia (mg/dL) 89 ± 4 102 ± 6 128 ± 6*** 112 ± 6**
Peptide-C (pmol/L) Fasting 1027.8 ± 71.4 2340.2 ± 73.7*** 1404.5 ± 73.7*** 2282.6 ± 187.9***
Non-fasting 1974.5 ± 163.8 5222.9 ± 374.1*** 3578.2 ± 256*** 4531.3 ± 432.8***
Insulin resistance (HOMA2-IR) 2.20 ± 0.15 3.35 ± 0.33 6.59 ± 0.67*** 5.36 ± 0.79*
Total cholesterol (mM) 2.92 ± 0.41 4.0 ± 0.80 3.44 ± 0.48 5.03 ± 0.73*
Effects of diet on body weight and metabolic parameters during the study, after 2 (M2) of normal diet (ND), normal diet + fructose (HF), high fat diet (HFD) and
HFD + fructose (HFHF). In bold significant difference with age-matched ND rats and abetween HFD- and HFHF-rats. *p<0.05, **p<0.01, ***p<0.001
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involving hyperinsulinaemia [40] and GSK-3 inactivation
[46]. Therefore, only this mechanism is involved in
glycogen increase in HFD rats, while both mechanisms
contribute to increased glycogen levels in rats that were
fed fructose.
In our study, only HFHF was found to induce the
development and progression of steatosis into NASH.
The factors causing progression of NAFLD to fibrosis
and cirrhosis have not been defined in humans, in part
because of the unavailability of human liver tissue for
studies. Nevertheless, a series of mechanisms acting in
synergy, or in stages, have been proposed to explain the
transition and development of NAFLD to NASH. Fac-
tors that appear to be crucial involve increase in the
vulnerability of steatotic hepatocytes, OS, alteration in
the metabolism of lipids, mitochondrial dysfunction,
and insulin resistance. The latter includes not only the
metabolic consequences of insulin resistance and hyperin-
sulinaemia, but also changes in output of adipocytokines
in fat tissue, which create a pro-inflammatory and poten-
tially pro-fibrotic state [18, 47]. In fact, HFHF-induced
NASH in this model is associated with fibrosis and macro-
phage infiltration, elevation of hepatic triglyceride level,
and OS. Moreover the level of leptin, which also has pro-
inflammatory properties and is considered an essential
mediator of hepatic fibrosis [48], was significantly higher
in HFHF than in HFD rats, despite the same weight gain
for each group. This may highlight a body fat abnormality
leading to higher hepatic complications [49]. These results
are in accordance with the ‘two-hits’ hypothesis of Day
and James [50], in which the accumulation of hepatic tri-
glycerides constitutes the first hit of NASH pathogenesis,
Table 4 Evolution of inflammatory and oxidative parameters during the study
M0 Ctr M0 Ctr
Plasmatic parameters Hepatic parameters
TNFα (pg/mL) 37.30 ± 13.68 Macrophages (% of area) 1.91 ± 0.4
TAOC (mmol/L trolox equivalent) 10.51 ± 0.29 Oxidative stress (% vs. age-matched ND) 100 ± 22.9
Lipids peroxidation (μmol/L TBARS) 20.6 ± 3.2 SOD activity (% inhibition rate) 0.97 ± 0.003
Catalase activity (μmol/L) 0.272 ± 0.03
Lipids peroxidation (μmol/L TBARS) 23 ± 0.8
M2 ND HF HFD HFHF
Plasmatic parameters
TNFα (pg/mL) 23.23 ± 7.82 13.63 ± 3.52 49.03 ± 20.06 13.84 ± 5.46
TAOC (mmol/L trolox equivalent) 7.64 ± 0.15 7.93 ± 0.16 7.58 ± 0.45 8.32 ± 0.25
Lipids peroxidation (μmol/L TBARS) 19.4 ± 2.0 41.9 ± 10.5 26.5 ± 5.3 43.3 ± 13.1
Hepatic parameters
Macrophages (% of area) 4.34 ± 1.1 2.88 ± 1.2 2.58 ± 0.8 4.10 ± 2.1
Oxidative stress (% vs. age-matched ND) 100 ± 11.4 108.1 ± 17.7 168.2 ± 17.3* 151 ± 17.9*
SOD activity (% inhibition rate) 1.15 ± 0.13 0.99 ± 0.008 1.17 ± 0.09 1.08 ± 0.07
Catalase activity (μmol/L) 0.243 ± 0.03 0.187 ± 0.02 0.283 ± 0.04 0.257 ± 0.02
Lipids peroxidation (μmol/L TBARS) 20.4 ± 1.1 23.9 ± 0.1** 19.4 ± 0.7 18 ± 1.4
M8 ND HF HFD HFHF
Plasmatic parameters
TNFα (pg/mL) 25.63 ± 7.57 48.90 ± 9.74 97.98 ± 28.42* 130.7 ± 40.68***
TAOC (mmol/L trolox equivalent) 11.07 ± 0.08 11.24 ± 0.19 10.96 ± 0.09 11.10 ± 0.27
Lipids peroxidation (μmol/L TBARS) 20.1 ± 2.5 22.5 ± 3.3 38.8 ± 3.8** 48.0 ± 6.3*
Hepatic parameters
Macrophages (% of area) 2.20 ± 1.5 2.37 ± 1.1 5.99 ± 1.9 11.26 ± 2.4**a
Oxidative stress (% vs. age-matched ND) 100 ± 6.3 110.2 ± 21.5 149.2 ± 15.3 206 ± 29.1**a
SOD activity (% inhibition rate) 1.09 ± 0.04 0.94 ± 0.08 1.13 ± 0.14 1.17 ± 0.16
Catalase activity (μmol/L) 0.246 ± 0.03 0.120 ± 0.03** 0.207 ± 0.03 0.232 ± 0.01
Lipids peroxidation (μmol/L TBARS) 18 ± 1.2 15.7 ± 2.0 18.9 ± 2.1 16.5 ± 1.1
Effects of diet on plasmatic and hepatic inflammation and oxidative parameters during the study, at the beginning (M0) and after 2 (M2) and 8 months (M8) of
normal diet (ND), normal diet + fructose (HF), high fat diet (HFD) and HFD + fructose (HFHF). In bold significant difference with age-matched ND rats and abetween
HFD- and HFHF-rats. *p<0.05, **p<0.01, ***p<0.001
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and OS followed by inflammation represents the second
hit.
Hepatocytes have an elaborate system of enzymatic
and non-enzymatic antioxidant defences to remove or
neutralize ROS [51]. However, excessive levels of ROS
may overwhelm the hepatocellular antioxidant defences,
resulting in OS, hepatocyte injury, and cell death. In our
model, HFHF and HFD rapidly induced hepatic OS,
highlighting that OS as an important inducer of hepatic
steatosis, whereas HF alone was neither associated with
OS nor with steatosis. Short periods of hyperglycaemia
are also able to induce OS [52], as observed after 2 months
of HFD (higher but not significant fasting glycaemia),
associated with steatosis. However, chronic hypergly-
caemia, in addition to fluctuations in glucose level and
hyperinsulinaemia (particularly in fasting conditions),
Fig. 2 Evolution of hepatic complications. a Severity of hepatic complications was assessed by eosin/hematoxylin coloration and Oil-Red O for
steatosis, Masson’s Trichrome for fibrosis, macrophages infiltration and oxidative stress by dihydroethidine (DHE) at the beginning (M0), after
2 (M2) and 8 (M8) months of normal diet (ND), normal diet + fructose (HF), high fat diet (HFD) and HFD + fructose (HFHF). The score of steatosis is
noted under the picture (0, 1, 2, or 3). Results for 5 different experiments are shown. Bar scale = 100 μm. b-c Quantification of hepatic triglycerides (b)
and glycogen (c) in frozen-liver tissue, at the beginning (M0), after 2 (M2) and 8 (M8) months of normal diet (ND), normal diet + fructose (HF), high fat
diet (HFD) and HFD+ fructose (HFHF). Results are shown as mean ± SEM of 5 different experiments. * Significant results versus age-matched ND-rats
and # between two groups
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leptin resistance, and inflammation exacerbate ROS for-
mation and maintain OS [20]. ROS are understood to
be important for the stimulating the production of type
I collagen by hepatic stellate cells, therefore increasing
extracellular matrix deposition during fibrogenesis [53].
These various disorders, which were observed in the
HFHF-rats, but not the HF rats, after 8 months, explain
the progression of NAFLD into NASH. Our results on
liver complications are in accordance with the study of
Rector et al. who demonstrated that mitochondrial
Fig. 3 Evolution of vascular complications: oxidative stress and vascular reactivity of mesenteric artery. a Higher panel. Visualization of dihydroethidine
(DHE) representative immunofluorescent staining of ROS in rats’ liver (a) and mesenteric artery (b) during the study, at the beginning
(M0) and after 2 (2M) and 8 (8M) months of normal diet (ND), normal diet + fructose (HF), high fat diet (HFD) and HFD + fructose (HFHF).
Bottom panel. Corresponding cumulative data. Results are shown as mean ± SEM of 5 different experiments. * Significant results versus
age-matched ND-rats and # between HFD- and HFHF-rats. Bar scale = 100 μm. b Concentration–relaxation curves to acetylcholine (ACh) in
mesenteric artery rings with endothelium from control-rats (M0), normal diet-rats (ND, ) after 8 months of diet and normal diet + fructose (HF, ●),
high fat diet (HFD, □) and HFD+ fructose (HFHF, ■). Experiments were performed in the presence of indomethacin (10−5 M) and Nω-nitro-L-arginine
(L-NA, 10−4 M) to rule out the formation of vasoactive prostanoids and NO, respectively (EDHF-mediated component). Results are shown as means ±
SEM of 5 different rats. *P < 0.05 represents a significant effect
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dysfunction progressively contributes to the develop-
ment of obesity-associated NAFLD in OLETF rats [54].
It can therefore be concluded that OS plays an import-
ant role in both the initial stages of steatosis, as well
as its progression, especially in fibrosis and NASH.
Several studies have reported an association between
NAFLD and cardiovascular disease-related complica-
tions (i.e. atherosclerosis) and hypothesise that common
inflammatory and/or OS mediators are involved in indu-
cing hepatic and peripheral vascular alterations [55]. In
our study, EDHF-mediated relaxations were found to be
blunted in the mesenteric artery of HFHF- and HFD-
rats after 8 months of diet, but no significant similar
effects were observed in rats fed the HF diet. Moreover,
while ageing induced blunted NO-mediated relaxation,
neither HF, HFD nor HFHF exacerbate this dysfunction
(data not shown). So, NO-mediated relaxations were not
affected by diets. These results are in accordance with
the reduction of EDHF observed in other models of T2D
(Goto-Katizaki rats, Zucker obese rats, and OLETF rats)
[56], which do not show any effect on NO. However,
studies of NO that report an increase, maintenance, or
reduction in relaxation [56] in other types of arteries,
species, and animals models may explain this variabil-
ity. Another factor that influences endothelial function
is the age of the animal. Indeed, previous studies have
shown that aging is associated with a rapid (20 weeks)
and progressive loss of endothelial function in rats [21].
In our study, after 8 months of treatment (at 10 months
of age), ND rats developed endothelial dysfunction
characterised by reduced NO- and EDHF-mediated re-
laxations in mesenteric arteries, without any effect on
pathways involved in the relaxation of smooth muscle
cells (data not shown). The same results were obtained
for the aorta, where NO is the most important relaxant
factor (data not shown). Therefore, in our study, only
the EDHF component of relaxation was found to be
blunted by HFHF and HFD after 8 months, in addition
to age-induced endothelial dysfunction. Recent studies
have reported that two factors are related to glucose-
induced OS: the glucose variability and the glucose mem-
ory. Therefore, the endothelial dysfunction observed in
HFD rats after 8 months may be explained in part by the
long-lasting deleterious effects of glucose, which persist
beyond the period of hyperglycaemia (observed only at
2 months), whereas HFHF rats have longer-lasting gly-
caemic fluctuation due to the persistence of glucose in-
tolerance and hyperglycaemia in these rats. In addition, a
number of disorders may induce endothelial dysfunction,
such as obesity, visceral fat distribution [57], impaired fast-
ing glucose, hyperglycaemia [58], insulin resistance [59],
oxidative stress [60], and inflammation [61] all of which
were observed in our models, and reported in other
studies [62].
Conclusions
Increased fat intake and Western diets have been linked
to insulin resistance, impaired postprandial lipid metab-
olism, and the development or progression of NAFLD.
However, data from recent animal experiments and hu-
man studies additionally implicate sugar consumption
(primarily in the form of soft drinks, worldwide) in the
development of diabetes mellitus and related metabolic
diseases that raise cardiovascular risk. The latest WHO
guidelines advise reducing sugar intake by 10 to 5 % of
the daily calorie intake, in order to provide additional
benefits. For many years, sugars (mainly fructose) have
been added to processed foods, and our taste preferences
are progressively shaped by more pronounced sweet fla-
vours. Recent scientific reports identify fructose as the
major player in the risk of developing T2D [62]. There-
fore, fructose is an essential and indispensable element to
consider for the development of an in vivo model of T2D
that is most representative of the pathophysiology of the
disease in humans. In our study, while the intake of fruc-
tose alone was found to accelerate metabolic disturbances
associated with increasing age (insulin resistance and glu-
cose intolerance), its association with HFD was found to
result in the development of metabolic syndrome in T2D
and liver and vascular complications. The administration
of a combination of fructose and lipids was found to be
ideal for the development of an experimentally induced
T2D model. These different in vivo models (HF, HFD, and
HFHF) should be useful as tools for testing candidates
(natural or synthetic) in drug development for a broad
spectrum of metabolic diseases.
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